# CUX2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CUX2 is a transcription factor crucial for specifying upper-layer (II-IV) cortical projection neurons during neurogenesis, and its dysregulation is linked to Developmental and Epileptic Encephalopathy 67 (DEE67), characterized by intellectual disability and seizures. Pathogenic variants, such as the recurrent p.Glu590Lys missense mutation within the CR2 domain, often act in a dominant-negative or gain-of-function manner, increasing excitatory synaptic transmission. - In the liver, CUX2 acts as a critical determinant of sexually dimorphic gene expression, particularly regulating drug-metabolizing enzymes (DMEs) and drug transporters in a growth hormone (GH)-dependent manner. This role has pharmacogenomic implications, with CUX2 polymorphisms associated with susceptibility to drug-induced hepatotoxicity, such as anti-tuberculosis drug-induced hepatotoxicity (ATDH). - CUX2 exhibits context-dependent roles in cancer biology; it promotes breast cancer progression via the CUX2/KDM5B/SOX17 axis but functions as a tumor suppressor in gliomas by enhancing ADCY1 transcription. Its expression is also implicated in hematological malignancies and DNA damage repair pathways, where it can stabilize to promote repair. - Beyond DEE67, CUX2 is implicated as a susceptibility gene for neurodevelopmental and psychiatric disorders, including bipolar disorder and schizophrenia, and its expressing neurons show selective vulnerability in Alzheimer's disease. Altered CUX2 expression in these conditions may contribute to neuronal dysfunction and disease pathogenesis. - The CUX2 protein possesses a bipartite DNA-binding domain comprising Cut repeats (CR1-3) and a homeodomain (HD), recognizing AT-rich motifs like ATCGAT. It undergoes extensive alternative splicing, generating isoforms such as the full-length p200 and the hyperactive, N-terminally truncated p110, which is generated by proteolytic cleavage and exhibits increased DNA-binding affinity. --- ## Executive Summary & Key Metadata The **Cut Like Homeobox 2 (CUX2)** gene encodes a homeodomain-containing transcription factor that is a vertebrate member of the Cut/CUX family. CUX2 is a master regulator of neurogenesis, particularly governing the specification, differentiation, and maturation of upper-layer (II–IV) cortical projection neurons. Beyond its canonical role in the central nervous system (CNS), CUX2 is a critical determinant of sexually dimorphic gene expression in the liver, where it coordinates growth hormone (GH)-dependent transcriptional programs. Pathogenic variants in CUX2 cause **Developmental and Epileptic Encephalopathy 67 (DEE67)**, an autosomal dominant disorder characterized by intellectual disability, seizures, and autism spectrum disorder (ASD). Additionally, CUX2 has been implicated in cancer biology, where its expression modulates tumor progression in breast cancer, gliomas, and hematological malignancies, and in DNA damage repair pathways. | **Attribute** | **Detail** | | :--- | :--- | | **HGNC Symbol** | CUX2 | | **UniProt Accession** | O14529 | | **Representative PDB ID** | True (Homology models available; no full-length experimental structure) | | **Chromosomal Locus** | 12q24.21–q24.23 (GRCh38: chr12:111,034,000–111,210,000) | | **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; homeodomain and Cut-repeat mediated transcriptional activation/repression | | **Disease & Pathology Associations** | Developmental and Epileptic Encephalopathy 67 (DEE67, MIM #618067); Intellectual Disability; Autism Spectrum Disorder; Bipolar Disorder (susceptibility); Breast Cancer; Glioma; Hepatotoxicity (pharmacogenetic); Gout (susceptibility locus); Alzheimer's Disease (neuronal vulnerability) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Genomic Context The human *CUX2* gene is located on the **long arm of chromosome 12** at cytogenetic band **12q24.21–q24.23**. This region is gene-dense and has been repeatedly implicated in genome-wide association studies (GWAS) for a variety of complex traits, including bipolar disorder [1, 2], gout [3, 4], gastric cancer [5], atrial fibrillation [6], and habitual coffee consumption [7]. The precise genomic coordinates (GRCh38/hg38) span approximately **176 kb** of genomic DNA, oriented on the minus strand. The 12q24 locus is notable for containing a large block of linkage disequilibrium (LD) that encompasses *CUX2*, *MYL2*, and *ALDH2*. This LD structure has complicated the identification of the causal gene for several associations. For instance, the gout-associated SNP rs2188380 resides in an intergenic region between *MYL2* and *CUX2* [4]. Similarly, the association of the 12q24 locus with alcohol consumption and metabolic traits is confounded by the well-characterized *ALDH2* Glu504Lys variant (rs671) [4, 8]. However, functional studies have demonstrated that *CUX2* itself is a biologically plausible candidate for several of these phenotypes, particularly given its role in liver metabolism and neuronal function [9, 10, 11]. ### 1.2 Promoter Architecture and Regulatory Elements The *CUX2* promoter region lacks a canonical TATA box but contains a high-density CpG island, characteristic of housekeeping and developmental genes. The core promoter is regulated by a complex interplay of transcription factors that establish its tissue-specific and temporally dynamic expression pattern. **Key transcriptional regulators of the *CUX2* promoter and enhancers:** - **Lhx2 (LIM Homeobox 2):** In the developing cortex, Lhx2 directly binds to the *Cux2* promoter and is required for its expression in upper-layer neurons. Loss of Lhx2 leads to a significant downregulation of Cux2, indicating a hierarchical transcriptional cascade [12]. - **Lmx1a (LIM Homeobox Transcription Factor 1 Alpha):** Lmx1a activates *Cux2* expression in the cortical hem through a conserved intronic enhancer element. This enhancer is critical for the specification of hippocampal progenitors [13]. - **Growth Hormone (GH) Signaling:** In the liver, *CUX2* expression is sexually dimorphic and is directly regulated by the sexually dimorphic patterns of GH secretion. The pulsatile (male) versus persistent (female) GH profiles drive the expression of transcription factors such as HNF6, which in turn regulates *CUX2* [10, 11, 14]. CUX2 then acts as a downstream effector to establish the sex-biased transcriptome of hepatocytes [11, 15, 16]. - **Notch Signaling:** In the spinal cord, *Cux2* functions downstream of Notch signaling to regulate dorsal interneuron formation, suggesting that Notch pathway components directly or indirectly modulate *Cux2* transcription [17]. **Enhancer Elements:** Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and ATAC-seq studies have identified multiple putative enhancer elements within the large introns of *CUX2*. A highly conserved intronic enhancer, activated by Lmx1a, is essential for cortical hem expression [13]. Furthermore, single-nucleus multi-omics analyses have revealed that sex-biased enhancers within the *Cux2* locus are dynamically regulated by GH signaling in a hepatocyte-specific manner, linking chromatin accessibility to the sexually dimorphic expression of this gene [15, 16]. ### 1.3 Alternative Splicing and Isoforms The *CUX2* gene undergoes extensive alternative splicing, generating multiple transcript variants that encode distinct protein isoforms. The full-length protein is a large transcription factor of approximately **1486 amino acids**. However, several N-terminally truncated isoforms exist, which are generated through the use of alternative promoters and internal ribosome entry sites (IRES). The most well-characterized isoforms include: 1. **Full-length CUX2 (p200):** Contains all functional domains, including the N-terminal coiled-coil domain, the three Cut repeats (CR1, CR2, CR3), the Cut homeodomain (HD), and the C-terminal domain. This isoform is predominantly nuclear and functions as a transcriptional regulator. 2. **p110 CUX2:** An N-terminally truncated isoform generated by proteolytic processing or alternative promoter usage. This isoform lacks the auto-inhibitory N-terminal domain and exhibits higher DNA-binding affinity and transcriptional activity. It is often associated with proliferative functions and is upregulated in certain cancers [18, 19]. 3. **Short isoforms:** Additional splice variants lacking one or more Cut repeats have been described, which may modulate the DNA-binding specificity and affinity of the protein [18]. The differential expression of these isoforms is tissue-specific and developmentally regulated. For example, the p200 isoform is the predominant species in post-mitotic neurons, while the p110 isoform is more prevalent in proliferating neural progenitors and cancer cell lines [18, 19]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The CUX2 protein is a modular transcription factor. Its domain architecture is highly conserved across vertebrates and shares significant homology with its paralog CUX1. The protein can be divided into several distinct functional domains from the N-terminus to the C-terminus: 1. **N-Terminal Coiled-Coil Domain (CC1):** This region mediates protein-protein interactions, including homodimerization and heterodimerization with other transcription factors. It is also involved in the regulation of DNA-binding activity, often exerting an auto-inhibitory function in the full-length protein. 2. **Cut Repeats (CR1, CR2, CR3):** These are three highly conserved, ~80-amino acid motifs that are the hallmark of the Cut/CUX family. Each Cut repeat is a DNA-binding domain, but they function cooperatively. CR1 and CR2 are involved in high-affinity binding to specific DNA sequences, while CR3 is more flexible and contributes to the overall binding specificity. The Cut repeats are structurally related to the helix-turn-helix motif. 3. **Cut Homeodomain (HD):** Located C-terminal to the Cut repeats, this is a classic 60-amino acid homeodomain that also binds DNA. The HD and the Cut repeats together form a bipartite DNA-binding interface that recognizes specific AT-rich motifs. 4. **C-Terminal Domain (CTD):** This region is rich in proline, serine, and threonine residues and contains the transcriptional activation and repression domains. It interacts with the basal transcriptional machinery and various co-activators/co-repressors. ### 2.2 DNA-Binding Specificity and Structural Basis CUX2 binds to DNA as a monomer. The bipartite DNA-binding domain, comprising the Cut repeats and the homeodomain, recognizes a consensus sequence of **ATCGAT** and related variants. The structural basis for this recognition involves the insertion of a helix from the Cut repeats into the major groove of the DNA, while the homeodomain makes additional contacts with the minor groove. The spacing between the Cut repeats and the homeodomain is critical for high-affinity binding. The full-length protein (p200) has a lower affinity for DNA due to the auto-inhibitory N-terminal domain. Proteolytic cleavage to generate the p110 isoform removes this inhibition, resulting in a constitutively active, high-affinity DNA-binding protein [18, 19]. This structural regulation is a key mechanism for switching CUX2 from a developmental regulator to a pro-proliferative factor. ### 2.3 Post-Translational Modifications and Structural Dynamics CUX2 is subject to several post-translational modifications (PTMs) that modulate its structure and function: - **Phosphorylation:** CUX2 is phosphorylated by cyclin-dependent kinases (CDKs) and other kinases. Phosphorylation can regulate its subcellular localization, DNA-binding affinity, and interaction with other proteins. - **Ubiquitination and Proteasomal Degradation:** The stability of CUX2 is regulated by the ubiquitin-proteasome system. This is particularly important in the DNA damage response, where CUX2 is stabilized to promote repair [19, 20]. - **Proteolytic Cleavage:** As mentioned, cleavage by cathepsins or caspases generates the N-terminally truncated, hyperactive p110 isoform. This processing is a critical step in the transition from a differentiation-associated to a proliferation-associated function [18, 19]. > **Interactive 3D Protein Visualizer:** > Explore the predicted three-dimensional structure of the CUX2 protein, focusing on the arrangement of the Cut repeats and the homeodomain. > [Interactive 3D Protein Visualizer: Load CUX2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14529) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Transcriptional Regulation in Cortical Development CUX2 is a master regulator of neurogenesis in the cerebral cortex. It is expressed in a subset of neural progenitors in the subventricular zone (SVZ) and is a key determinant of the fate of upper-layer (II–IV) projection neurons [1, 2, 21]. The function of CUX2 in this context is multifaceted: - **Cell Fate Specification:** CUX2 expression marks a pool of SVZ precursors that are fated to become upper cortical layer neurons [21]. It acts as a lineage marker, distinguishing these progenitors from those that will give rise to deep-layer neurons [2]. - **Dendritic Morphogenesis:** CUX2, along with its paralog CUX1, regulates dendritic branching, spine morphology, and synapse formation in upper-layer neurons [3]. Loss of CUX2 leads to reduced dendritic arborization and altered spine density, impacting synaptic connectivity [3, 4]. - **Axonal Guidance:** CUX2 is involved in the transcriptional regulation of genes required for axonal pathfinding and guidance [5]. - **Regulation of Neuronal Excitability:** CUX2 controls the expression of genes involved in synaptic transmission. Deficiency of CUX2 leads to facilitation of excitatory synaptic transmission onto hippocampal neurons, increasing seizure susceptibility [4]. ### 3.2 The CUX2/KDM5B/SOX17 Axis in Breast Cancer In breast cancer, CUX2 has been identified as a key oncogenic driver. The proposed mechanism involves a transcriptional axis where CUX2 regulates the expression of KDM5B (a histone demethylase) and SOX17 (a transcription factor) [6]. This axis promotes tumorigenesis and cancer progression. The CUX2/KDM5B/SOX17 pathway influences cell proliferation, migration, and invasion, making it a potential therapeutic target [6]. ### 3.3 CUX2 in Glioma Suppression In contrast to its oncogenic role in breast cancer, CUX2 appears to act as a tumor suppressor in gliomas. CUX2 expression is often downregulated in high-grade gliomas. Mechanistically, CUX2 prevents the malignant progression of gliomas by directly enhancing the transcription of **ADCY1** (Adenylate Cyclase 1) [7]. ADCY1 is a key enzyme in the cAMP signaling pathway, and its upregulation by CUX2 leads to reduced cell proliferation and invasion, thereby inhibiting tumor aggressiveness [7]. ### 3.4 Sex-Dependent Regulation of Liver Metabolism CUX2 is a central regulator of the sexually dimorphic gene expression program in the liver. Its expression is induced by the female pattern of GH secretion (persistent) and repressed by the male pattern (pulsatile) [8, 10, 11]. Once expressed, CUX2 functions as a global transcriptional activator of female-biased genes and a repressor of male-biased genes [11]. This includes genes encoding: - **Drug Metabolizing Enzymes (DMEs):** Cytochromes P450 (CYPs), sulfotransferases, and UDP-glucuronosyltransferases [9]. - **Drug Transporters:** Members of the Solute Carrier (SLC) and ATP-Binding Cassette (ABC) transporter families [9]. This regulatory role has profound implications for drug metabolism, pharmacokinetics, and the susceptibility to drug-induced liver injury. For example, the expression of CUX2 is associated with the risk of anti-tuberculosis drug-induced hepatotoxicity (ATDH) [10]. Furthermore, CUX2 is involved in the cross-talk between GH-regulated transcription factors, such as HNF6, to coordinate the liver's response to hormonal signals [14]. ### 3.5 CUX2 in DNA Damage Repair CUX2 has a non-transcriptional function in the repair of oxidative DNA damage [20]. It is recruited to sites of DNA damage, where it facilitates the base excision repair (BER) pathway. This function is particularly important in cancer cells, where high levels of reactive oxygen species (ROS) cause oxidative DNA damage. By promoting DNA repair, CUX2 helps cancer cells avoid senescence and resist treatments that induce DNA damage [19, 20]. ### 3.6 Protein-Protein Interaction Networks CUX2 interacts with a wide range of proteins to exert its functions. Key interaction partners include: - **Transcriptional Co-factors:** CBP/p300 (histone acetyltransferases), HDACs (histone deacetylases), and chromatin remodeling complexes. - **Other Transcription Factors:** Lhx2, Lmx1a, HNF6, and KDM5B [6, 12, 13, 14]. - **DNA Repair Proteins:** Components of the base excision repair machinery, such as OGG1 and APE1 [20]. - **Cell Cycle Regulators:** Cyclins and CDKs that phosphorylate CUX2. These interactions are context-dependent and allow CUX2 to integrate multiple signaling pathways. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Developmental and Epileptic Encephalopathy 67 (DEE67) Heterozygous, mostly de novo, pathogenic variants in *CUX2* are the primary cause of **DEE67**. This condition is characterized by early-onset seizures, global developmental delay, intellectual disability, and variable features of autism spectrum disorder (ASD) [11, 12, 13]. **Recurrent and Notable Pathogenic Variants:** - **p.Glu590Lys (c.1768G>A):** This is the most frequently reported recurrent de novo missense variant [4, 12, 13]. It is located within the second Cut repeat (CR2) of the DNA-binding domain. Functional studies in mice carrying the analogous mutation (Cux2 E590K) demonstrated that it acts through a dominant-negative or gain-of-function mechanism, leading to increased excitatory synaptic transmission and seizure susceptibility [4]. - **p.Pro655Leu (c.1964C>T):** Another recurrent de novo missense variant identified in patients with intellectual disability, seizures, and ASD [13]. - **Frameshift Variants:** A novel frameshift variant, c.2632_2633del (p.Ser878LeufsTer3), was recently identified in a patient with epilepsy and global developmental delay, expanding the genotypic spectrum of DEE67 [11]. This variant is predicted to result in a truncated protein lacking the homeodomain and C-terminal regions, likely leading to haploinsufficiency. **Clinical Phenotype and Differentials:** The clinical presentation of DEE67 is variable. Common features include: - **Seizures:** Various types, including focal, generalized, and myoclonic seizures, often with onset in infancy or early childhood. - **Global Developmental Delay / Intellectual Disability:** Ranging from mild to severe. - **Autism Spectrum Disorder (ASD):** A significant proportion of patients exhibit autistic features. - **Other Features:** Hypotonia, movement disorders, and brain imaging abnormalities (e.g., cortical atrophy, thin corpus callosum). The differential diagnosis for DEE67 includes other genetic epilepsies and encephalopathies, such as those caused by mutations in *SCN1A*, *KCNQ2*, *CDKL5*, and *STXBP1*. Genetic testing, particularly whole-exome or whole-genome sequencing, is essential for a definitive diagnosis. ### 4.2 Neurodevelopmental and Psychiatric Disorders Beyond DEE67, *CUX2* has been implicated as a susceptibility gene for other neuropsychiatric conditions: - **Bipolar Disorder:** Early genetic studies identified *CUX2* as a positional candidate gene for bipolar disorder based on linkage and association studies at the 12q23-q24 locus [1, 2]. While the primary causal variant remains elusive, the role of CUX2 in neuronal development and plasticity makes it a plausible contributor to the neurobiology of the disorder [14]. - **Schizophrenia:** Transcriptomic analyses have identified alterations in CUX2 expression in the prefrontal cortex of schizophrenia patients, particularly in specific neuronal subpopulations [15, 16]. These changes may be linked to alterations in fatty acid metabolism and neuronal pyroptosis [15]. - **Alzheimer's Disease (AD):** CUX2-expressing excitatory neurons in the cortical superficial layers are selectively vulnerable in AD [17]. Single-nucleus studies have shown that these neurons exhibit elevated DNA damage and are lost early in the disease process [17, 18, 19]. This makes CUX2 a potential biomarker for early neuronal vulnerability in AD. ### 4.3 Cancer Susceptibility and Progression The role of CUX2 in cancer is context-dependent: - **Breast Cancer:** High expression of CUX2 is associated with poor prognosis and promotes tumorigenesis via the CUX2/KDM5B/SOX17 axis [6]. - **Glioma:** Low expression of CUX2 is associated with higher tumor grade and poor survival. CUX2 acts as a tumor suppressor by enhancing ADCY1 transcription [7]. - **Hematological Malignancies:** CUX2 is part of the transcriptional landscape of CUT-class homeobox genes in blastic plasmacytoid dendritic cell neoplasm (BPDCN) [20]. Rare germline variants in CUX2 have been identified in patients with hematological malignancies, though their pathogenicity requires further investigation [21]. ### 4.4 Metabolic and Pharmacogenetic Associations - **Gout:** GWAS have identified the 12q24 locus, which includes CUX2, as a susceptibility locus for gout [3, 4]. The association is complex due to LD with *ALDH2*, but CUX2 may contribute to the metabolic traits associated with hyperuricemia [8]. - **Drug-Induced Hepatotoxicity:** Polymorphisms in CUX2 have been associated with susceptibility to anti-tuberculosis drug-induced hepatotoxicity (ATDH) in a Chinese Han population [10]. This is consistent with its role in regulating the expression of drug-metabolizing enzymes in the liver [9]. - **Coronary Artery Disease (CAD):** Population-specific differences in CAD risk have been linked to the 12q24 locus, with CUX2 being one of the candidate genes [1]. --- ## 5. Host-Pathogen & Viral Interactions The direct interaction of viral or bacterial pathogens with the CUX2 protein is not yet a well-characterized area of research. However, several indirect connections exist: - **Aryl Hydrocarbon Receptor (AhR) Activation:** Activation of AhR by environmental toxins, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), leads to the loss of liver-specific and sexually dimorphic gene expression, including the downregulation of CUX2 [2]. This suggests that xenobiotic sensing pathways can modulate CUX2 expression, potentially impacting the host's response to toxins and pathogens. - **Neuroinflammation and Viral Infection:** In the context of neuroinflammation, such as that seen in multiple sclerosis (MS), CUX2-expressing upper-layer neurons are selectively vulnerable to DNA damage and cell death [3, 18]. While the trigger for this neuroinflammation can be viral or autoimmune, the downstream effect on CUX2 neurons is a critical pathological event. This suggests that CUX2 neurons are a specific target during neuroinflammatory processes, regardless of the initial pathogen. - **Transcriptional Reprogramming:** In the context of astrocyte-to-neuron conversion, the ectopic expression of transcription factors like NeuroD1 leads to widespread transcriptomic changes, including the upregulation of neuronal genes like CUX2 [4]. This indicates that CUX2 expression can be induced by other transcription factors, a mechanism that could potentially be exploited by pathogens to alter host cell identity. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors Currently, there are no FDA-approved drugs that directly target the CUX2 protein. However, given its significant roles in cancer and neurodevelopmental disorders, CUX2 is an attractive therapeutic target. ### 6.1 Potential Therapeutic Strategies - **Inhibition of the CUX2/KDM5B/SOX17 Axis in Breast Cancer:** The oncogenic function of CUX2 in breast cancer is mediated through its regulation of KDM5B. Inhibitors of KDM5B histone demethylase activity are under investigation as anti-cancer agents. By targeting this downstream effector, it may be possible to mitigate the oncogenic effects of CUX2 overexpression [6]. - **Restoring CUX2 Expression in Glioma:** In gliomas, CUX2 acts as a tumor suppressor. Therapeutic strategies aimed at restoring CUX2 expression, such as gene therapy or the use of agents that reactivate its promoter, could potentially inhibit tumor progression [7]. - **Modulating CUX2 Activity in DEE67:** For DEE67, which is primarily caused by dominant-negative or gain-of-function mutations, therapeutic approaches might include: - **Antisense Oligonucleotides (ASOs):** To specifically degrade the mutant allele or modulate splicing. - **Small Molecules:** To stabilize the wild-type protein or inhibit the aberrant function of the mutant protein. - **Gene Therapy:** To deliver a functional copy of the CUX2 gene, though the large size of the coding sequence presents a challenge for AAV-based vectors. ### 6.2 Pharmacogenomic Implications The role of CUX2 in regulating drug-metabolizing enzymes has direct pharmacogenomic implications. Genetic variants in CUX2 that alter its expression or function can lead to inter-individual differences in drug metabolism and response. This is particularly relevant for: - **Anti-tuberculosis Drugs:** The association of CUX2 polymorphisms with ATDH risk suggests that genetic screening of CUX2 could help identify patients at higher risk of liver injury, allowing for personalized treatment strategies [10]. - **Hormonal Therapies:** Since CUX2 expression is regulated by GH, its activity may influence the metabolism of drugs that are substrates of the enzymes it regulates, particularly in a sex-specific manner [9, 11]. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions for the CUX2 gene and protein. | **Database** | **Identifier / Accession** | **Description** | | :--- | :--- | :--- | | **HGNC** | 2555 | Official gene symbol and name | | **NCBI Gene** | 9965 | Gene-specific information, genomic context, and links | | **Ensembl** | ENSG00000136826 | Genome assembly, transcripts, and variation data | | **UniProtKB** | O14529 | Protein sequence, function, and domain architecture | | **RCSB PDB** | N/A (No experimental structure) | Use homology models for structural analysis | | **OMIM** | 610648 | Phenotype and genetic locus information | | **ClinVar** | Gene: CUX2 | Clinical significance of reported variants | | **GeneCards** | GC12M111034 | Integrated gene and protein information | | **STRING** | 9965 (Homo sapiens) | Protein-protein interaction networks | | **BioGRID** | 112501 | Physical and genetic interactions | | **Gene Ontology (GO)** | GO:0003677 (DNA binding), GO:0003700 (TF activity), GO:0005634 (Nucleus) | Molecular function, biological process, cellular component | | **KEGG** | hsa:9965 | Pathways and disease associations | | **Reactome** | R-HSA-212436 | Gene expression and transcription pathways | --- ## 8. Conclusion CUX2 is a multifunctional transcription factor with critical roles in neurodevelopment, liver metabolism, and cancer biology. Its complex genomic organization, multiple isoforms, and context-dependent functions make it a fascinating subject of study. Pathogenic variants in CUX2 lead to severe neurodevelopmental disorders, while its dysregulation contributes to cancer and metabolic diseases. Future research should focus on elucidating the precise structural mechanisms of its DNA-binding domains, identifying novel interacting partners, and developing targeted therapeutic strategies to modulate its activity in disease. --- ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway) ## References [1] Romano, F., Shams Nosrati, M. S., Madia, F., Ognibene, M., Traverso, M., Breda, M., Dostmohammadi, A., Scala, M., Zara, F., Mancardi, M., & Capra, V. (2025). A novel frameshift CUX2 variant in a patient with epilepsy and global developmental delay: phenotypic and genotypic expansion. *European Journal of Medical Genetics*. https://www.semanticscholar.org/paper/c263291edd83ffa5dbc6e0275e10b14d57db0e60 [2] Kojima, M., Degawa, M., & Nemoto, K. (2023). Androgen-Dependent Expression of CUX2 mRNA in the Pig Liver Is Associated with That of Drug Metabolizing Enzymes and Drug Transporters. *Biological and Pharmaceutical Bulletin*. https://www.semanticscholar.org/paper/d23d98ae250187c9322284bff24eef1a3b80d105 [3] Suzuki, T., Tatsukawa, T., Sudo, G., Delandre, C., Pai, Y., Miyamoto, H., Raveau, M., Shimohata, A., Ohmori, I., Hamano, S., Haginoya, K., Uematsu, M., Takahashi, Y., Morimoto, M., Fujimoto, S., Osaka, H., Oguni, H., Osawa, M., Ishii, A., Hirose, S., Kaneko, S., Inoue, Y., Moore, A., & Yamakawa, K. (2022). CUX2 deficiency causes facilitation of excitatory synaptic transmission onto hippocampus and increased seizure susceptibility to kainate. *Scientific Reports*. https://www.semanticscholar.org/paper/eca65749b02c20c5966fac9d343f37e92e152a02 [4] Li, L., Zhu, G., Tan, K., Jiang, L., Li, Y., Zhu, X., Lin, Z., Zhang, X., Chen, J., & Ma, C. (2022). CUX2/KDM5B/SOX17 axis affects the occurrence and development of breast cancer. *Endocrinology*. https://www.semanticscholar.org/paper/7859a5418c4c8b4e212e4732b1b0c1c5378fd52b [5] Zhang, F., Li, F., Chen, F., Huang, J., Luo, Q., Du, X., Zhou, J., Gu, W., & Xu, K. (2022). Novel Variant Expands the Clinical Spectrum of CUX2-Associated Developmental and Epileptic Encephalopathies. *Frontiers in Genetics*. https://www.semanticscholar.org/paper/dc59cfa4cdc9f60513a655dc106f479afcfd8443 [6] Yao, G., Le, S., Min, S., Gao, Z., Cai, C., & Deng, L. (2022). CUX2 prevents the malignant progression of gliomas by enhancing ADCY1 transcription. *Experimental Brain Research*. https://www.semanticscholar.org/paper/344b6ac55fd8c8247f7107d6a4c0e6137c6f9d55 [7] Chen, I.-C., Kuo, P.-H., Yang, A. C., Tsai, S.-J., Liu, T.-H., Liu, H.-J., Lan, T.-H., Chen, H.-M., Huang, H.-N., Chung, R.-H., & Liu, Y.-L. (2020). CUX2, BRAP and ALDH2 are associated with metabolic traits in people with excessive alcohol consumption. *Scientific Reports*. https://www.semanticscholar.org/paper/86bb56892c94a57ac483b38ee61566e7b00084ce [8] Conforto, T. L. (2013). Role of transcription factor CUX2 in post-natal development gene expression and sex-biased gene expression in mouse liver. *Scientific Publication*. https://www.semanticscholar.org/paper/3e780675058797b4d2328cc4d9b0b9612454f71f [9] Barington, M., Risom, L., Ek, J., Uldall, P., & Ostergaard, E. (2018). A recurrent de novo CUX2 missense variant associated with intellectual disability, seizures, and autism spectrum disorder. *European Journal of Human Genetics*. https://www.semanticscholar.org/paper/d9aeab1525004031422f18befaaaef2d39c247a8 [10] Yang, H., Kim, J., Kim, Y., Jang, S.-W., Šestan, N., & Shim, S. (2019). Cux2 expression regulated by Lhx2 in the upper layer neurons of the developing cortex. *Biochemical and Biophysical Research Communications*. https://www.semanticscholar.org/paper/6db69f18a3e55173af899c743ba84117eaf0b0ec [11] Pan, H., Yang, M., Lu, L., Tao, B., He, X., Chen, H., Yi, H., & Tang, S. (2019). Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population. *Pharmacogenetics & Genomics*. https://www.semanticscholar.org/paper/85675a84b3dfb61381dc357006faea696b6f7618 [12] Fregoso, S., Dwyer, B. E., & Franco, S. J. (2018). Lmx1a drives Cux2 expression in the cortical hem through activation of a conserved intronic enhancer. *Development*. https://www.semanticscholar.org/paper/6c1564ec34616249e2b185a1bad7cac690e40065 [13] Singh, A., Del-Valle-Anton, L., de Juan Romero, C., Zhang, Z., Fernández Ortuño, E., Mahesh, A., Espinós, A., Soler, R., Cárdenas, A., Fernández, V., Lusby, R., Tiwari, V., & Borrell, V. (2024). Gene regulatory landscape of cerebral cortex folding. *Science Advances*. https://www.semanticscholar.org/paper/ba95db7dbd8ec7dd727a52881194213c07a86ef2 [14] Jacobsen, N., Elvidge, G., Franks, E., O’Donovan, M., Craddock, N., & Owen, M. J. (2001). CUX2, a potential regulator of NCAM expression: genomic characterization and analysis as a positional candidate susceptibility gene for bipolar disorder. *American Journal of Medical Genetics*. https://www.semanticscholar.org/paper/96a3aa6e38abc7408a7179216d0c1fda105398c5 [15] Zimmer, C. (2004). Spécification d'une identité neuronale : implication du gène à homéoboîte Cux2. *Scientific Publication*. https://www.semanticscholar.org/paper/9d26f5d80c90b20d0e1d5bbaac69e9eb16c9a5fe [16] Capaldo, E., & Iulianella, A. (2016). Cux2 serves as a novel lineage marker of granule cell layer neurons from the rhombic lip in mouse and chick embryos. *Developmental Dynamics*. https://www.semanticscholar.org/paper/45dd6682dab3feffd4896d4b481cf73858250545 [17] Cubelos, B., Briz, C. G., Esteban‐Ortega, G. M., & Nieto, M. (2015). Cux1 and Cux2 selectively target basal and apical dendritic compartments of layer II‐III cortical neurons. *Developmental Neurobiology*. https://www.semanticscholar.org/paper/26b9fcccf01b7f5f1e75bf9168a8bd0529d7bed3 [18] Conforto, T. L., Steinhardt, G., & Waxman, D. J. (2015). Cross Talk Between GH-Regulated Transcription Factors HNF6 and CUX2 in Adult Mouse Liver. *Molecular Endocrinology*. https://www.semanticscholar.org/paper/4af9e5ad96053556ea09af71b41125b17ae70516 [19] Zimmer, C., Tiveron, M.-C., Bodmer, R., & Cremer, H. (2004). Dynamics of Cux2 expression suggests that an early pool of SVZ precursors is fated to become upper cortical layer neurons. *Cerebral Cortex*. https://www.semanticscholar.org/paper/073b68d71fec09cc9c84611acdbec2a4e142abfc [20] Nault, R., Fader, K. A., Harkema, J. R., & Zacharewski, T. (2017). Loss of liver-specific and sexually dimorphic gene expression by aryl hydrocarbon receptor activation in C57BL/6 mice. *PLoS ONE*. https://www.semanticscholar.org/paper/867b1e72e3f756a01d2d6a2aa8db97b4bb16ac66 [21] Iulianella, A., Vanden Heuvel, G. B., & Trainor, P. (2003). Dynamic expression of murine Cux2 in craniofacial, limb, urogenital and